JHVEPhoto Shares of Cartesian Therapeutics ( NASDAQ: RNAC ) rose 8% in morning trading Wednesday after the company said it received FDA regenerative medicine advanced therapy, or RMAT, designation for its drug candidate Descartes-08 in the treatment of myasthenia gravis. Cartesian said it expects to report topline results mid-year from a Phase 2b study of the mRNA CAR-T cell therapy in the treatment of myasthenia gravis. Descartes-08 also has FDA orphan drug designation for the condition.
More on Cartesian Therapeutics Cartesian Therapeutics GAAP EPS of -$1.66 misses by $1.64, revenue of $26M beats by $15.
4M Historical earnings data for Cartesian Therapeutics Financial information for Cartesian Therapeutics.